BR112013001302A2 - métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma - Google Patents

métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma

Info

Publication number
BR112013001302A2
BR112013001302A2 BR112013001302A BR112013001302A BR112013001302A2 BR 112013001302 A2 BR112013001302 A2 BR 112013001302A2 BR 112013001302 A BR112013001302 A BR 112013001302A BR 112013001302 A BR112013001302 A BR 112013001302A BR 112013001302 A2 BR112013001302 A2 BR 112013001302A2
Authority
BR
Brazil
Prior art keywords
methods
receptor mediated
amide derivatives
cyclic amide
mediated disorders
Prior art date
Application number
BR112013001302A
Other languages
English (en)
Inventor
N Karabelas Argeris
Pellegrini Lorenzo
Henri Luthringer Remy
Original Assignee
Cyrenaic Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyrenaic Pharmaceuticals Inc filed Critical Cyrenaic Pharmaceuticals Inc
Publication of BR112013001302A2 publication Critical patent/BR112013001302A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma. são revelados aqui composições e métodos para tratar um distúrbios ou condição medida por receptor de sigma-2, incluindo tratar um ou mais sintomas de um distúrbios ou condição mediada por receptor de sigma-2.
BR112013001302A 2010-07-20 2011-07-20 métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma BR112013001302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36608010P 2010-07-20 2010-07-20
PCT/US2011/044698 WO2012012543A1 (en) 2010-07-20 2011-07-20 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders

Publications (1)

Publication Number Publication Date
BR112013001302A2 true BR112013001302A2 (pt) 2017-07-04

Family

ID=45497167

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001302A BR112013001302A2 (pt) 2010-07-20 2011-07-20 métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma

Country Status (15)

Country Link
US (3) US20130274290A1 (pt)
EP (2) EP4070794A3 (pt)
JP (3) JP2013531073A (pt)
KR (1) KR101867634B1 (pt)
CN (2) CN103108548A (pt)
BR (1) BR112013001302A2 (pt)
CA (2) CA2805904C (pt)
DK (1) DK2595485T3 (pt)
ES (1) ES2914120T3 (pt)
HU (1) HUE058736T2 (pt)
PL (1) PL2595485T3 (pt)
PT (1) PT2595485T (pt)
RU (2) RU2613201C2 (pt)
TW (1) TWI520949B (pt)
WO (1) WO2012012543A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
WO2015191554A1 (en) * 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
EA201791226A1 (ru) * 2014-12-02 2017-09-29 Минерва Ньюросайенсиз, Инк. Композиции, содержащие 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения шизофрении
SG11201810358YA (en) * 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
BR112019027398A2 (pt) * 2017-06-21 2020-07-07 Minerva Neurosciences, Inc. formas de dosagem orais de liberação controlada gastrorresistente
WO2020041504A1 (en) * 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903857A1 (en) * 1989-10-27 1991-05-08 Du Pont Merck Pharma (N-Phthalimidoalkyl)Piperidines
WO1991006297A1 (en) * 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
DK0637306T3 (da) * 1992-04-23 2001-07-30 Merrell Pharma Inc 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
DE60129210T2 (de) * 2000-02-29 2008-03-20 Mitsubishi Pharma Corp. Zyklische amid-derivate
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
EP2595485A4 (en) 2014-04-23
PL2595485T3 (pl) 2022-06-20
HUE058736T2 (hu) 2022-09-28
ES2914120T3 (es) 2022-06-07
JP6419294B2 (ja) 2018-11-07
TWI520949B (zh) 2016-02-11
JP2018065829A (ja) 2018-04-26
EP2595485A1 (en) 2013-05-29
RU2017105262A (ru) 2019-01-18
KR101867634B1 (ko) 2018-06-15
RU2017105262A3 (pt) 2019-01-18
JP2013531073A (ja) 2013-08-01
JP2016199578A (ja) 2016-12-01
EP2595485B1 (en) 2022-03-16
EP4070794A3 (en) 2023-01-18
RU2746871C2 (ru) 2021-04-21
PT2595485T (pt) 2022-05-30
KR20130129906A (ko) 2013-11-29
CA2805904C (en) 2022-06-21
CA3154027A1 (en) 2012-01-26
US20210106573A1 (en) 2021-04-15
EP4070794A2 (en) 2022-10-12
RU2013107378A (ru) 2014-08-27
DK2595485T3 (da) 2022-05-30
RU2613201C2 (ru) 2017-03-15
TW201211022A (en) 2012-03-16
CN107007603A (zh) 2017-08-04
US20130274290A1 (en) 2013-10-17
CA2805904A1 (en) 2012-01-26
CN103108548A (zh) 2013-05-15
US20160354357A1 (en) 2016-12-08
WO2012012543A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
BR112013001302A2 (pt) métodos de uso de derivados de amida cíclica para tratar distúrbios mediados por receptor de sigma
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
SA515360928B1 (ar) متقارنات جسم مضاد جديدة واستخداماتها
CU20130115A7 (es) Compuestos y composiciones como inhibidores de trk
MX2016002571A (es) Regulador de ph de transduccion.
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2015002873A (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
BR112016009630A8 (pt) receptores de farnesoide x, seus usos, composição farmacêutica, e combinação
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
TR201901886T4 (tr) DNA-PK inhibitörleri.
PH12017500864A1 (en) Anti-notch1 antibodies
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
GEP20166444B (en) Epoxyeicosatrienoic acid analogs and methods of making and using the same
PH12015501053B1 (en) Oxazolidin-2-one-pyrimidine derivatives
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201490268A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201691413A1 (ru) Селективные антагонисты nr2b
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
BR112013001303A2 (pt) métodos de uso de derivados de amida cíclica para tratar esquizofrenia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/40 , A61K 31/445 , C07D 217/00 , C07D 217/02 , C07D 217/22 , C07D 401/00

Ipc: C07D 401/00 (2006.01), A61K 31/445 (2006.01), C07D

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL